Management of Chronic Headache Unresponsive to Duloxetine and Acetaminophen

First‑Line Acute Therapy

The 2025 American College of Physicians (ACP) guideline recommends adding a triptan to the current acetaminophen regimen when the patient is already using adequate acetaminophen doses but still lacks sufficient relief. 1
Acceptable triptan agents include almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan; the choice should be guided by the patient’s preferred route of administration and cost considerations. [1][2]
If NSAIDs are not contraindicated, a triptan should be combined with an NSAID (e.g., naproxen 500‑825 mg or ibuprofen 400‑800 mg) because this combination provides superior efficacy compared with a triptan‑acetaminophen pairing. [1][4]

Replace acetaminophen with an NSAID (naproxen, ibuprofen, aspirin, diclofenac, or celecoxib) because acetaminophen alone has limited evidence for migraine relief. [4][5]

When a triptan + NSAID regimen fails or is not tolerated, CGRP receptor antagonists (rimegepant, ubrogepant, or zavegepant) are recommended for moderate‑to‑severe headache attacks; efficacy is supported, although head‑to‑head comparative data are limited. [1][2]
Dihydroergotamine (DHE) administered as a nasal spray or injection may be effective as an alternative; it is contraindicated in pregnancy and should not be combined with triptans. [1][6]
Lasmiditan (a ditan) is reserved as a last‑resort acute agent when other treatments have failed. [1][7]

MOH should be screened for by evaluating medication frequency: ≥15 days/month of NSAID use or ≥10 days/month of triptan use defines overuse. [1][3]
MOH is a common pitfall that can perpetuate chronic headache syndromes. 1

Preventive medication should be added when headache attacks are frequent or acute treatment is inadequate. [1][8]
The 2024 VA/DoD guideline advises initiating preventive therapy for patients experiencing ≥2 attacks per month that cause ≥3 days of disability. 9
First‑line preventive options include propranolol (80‑240 mg/day), amitriptyline (30‑150 mg/day), topiramate, valproate, and CGRP monoclonal antibodies. [10][9]

Opioids and butalbital‑containing compounds should be avoided in chronic headache management because they increase the risk of dependency, medication‑overuse headache, and loss of efficacy. [1][2]5

For prominent nausea, add an antiemetic such as metoclopramide or prochlorperazine. 5
In cases of severe nausea, consider non‑oral triptan formulations (nasal spray or subcutaneous) together with an antiemetic. [1][2]
Aerobic exercise and physical therapy have evidence supporting benefit for both tension‑type headache and migraine. 9
Lifestyle modifications—including adequate hydration, regular meals, consistent sleep patterns, and stress‑management strategies—should be reinforced. [1][8]

Verify that the patient is using an adequate acetaminophen dose (1 g per dose, maximum 4 g/day) before adding other agents; if the current dose is sub‑therapeutic, increase to the recommended maximum prior to escalation. [2][3]